Call for Applications: Discovery Grant Program (Canada)

Deadline: 03-Jul-2026

The Discovery Grant Program is designed to advance research on amyotrophic lateral sclerosis and related neurological diseases in Canada. It supports projects that can identify disease causes, improve treatment approaches, and strengthen quality of life for people and families living with ALS.

The program is intentionally collaborative and translational. It encourages multidisciplinary teams and research that can move toward clinical impact, rather than remaining purely theoretical.

Key facts

• Funder: Brain Canada Foundation.

• Country: Canada.

• Research area: ALS and related neurological diseases.

• Total funding envelope: CAD 1,500,000.

• Funding streams: Seed Grant and Development Grant.

• Seed Grant: Up to CAD 125,000 over two years.

• Development Grant: Up to CAD 500,000 over three years.

• Award notice: November 2026.

• Funding start: January 2027.

What the program supports

The program supports research focused on:

• Identifying causes of ALS and related disorders.

• Developing treatments.

• Improving function and reducing disability.

• Enhancing quality of life for patients and families.

• Understanding disease mechanisms.

• Symptom management.

• Psychological interventions.

• Nutritional care.

• Respiratory care.

• Caregiver support.

• Engineering-based approaches to reduce physical limitations.

It also includes related neurological diseases such as primary lateral sclerosis, progressive muscular atrophy, and ALS/FTLD.

Funding streams

Seed Grant

The Seed Grant supports early-stage or high-risk ideas that may generate preliminary data. It is intended for projects with strong potential but less mature evidence.

• Amount: Up to CAD 125,000.

• Duration: Two years.

• Best for: Novel ideas and early-stage concepts.

Development Grant

The Development Grant supports projects with stronger preliminary data and a clearer path to translational impact. It is meant to advance projects toward human relevance and eventual application.

• Amount: Up to CAD 500,000.

• Duration: Three years.

• Best for: More developed projects with translational potential.

Eligibility

The program is open to research teams capable of conducting ALS-related scientific or clinical research. Applicants should be prepared to work in collaborative, multidisciplinary teams.

Competitive applications will usually include:

• Strong scientific rationale.

• Feasible experimental design.

• Relevant expertise across disciplines.

• Alignment with ALS research priorities.

• A realistic path to impact.

Review process

Applications are assessed through peer review. Reviewers consider:

• Scientific merit.

• Feasibility.

• Innovation.

• Alignment with ALS priorities.

Funding distribution between the two streams depends on the quality of applications and the peer review outcomes.

What strong applications should show

A strong proposal should demonstrate:

• A clear ALS-related research question.

• Why the work matters now.

• How the team’s expertise is complementary.

• Why the methods are feasible.

• Whether the project is early-stage or data-supported.

• How the work could lead to clinical or practical impact.

Why it matters

This program matters because ALS research needs both bold new ideas and well-developed translational projects. By supporting both early-stage exploration and larger, more advanced studies, the program helps build a pipeline of research progress.

It also matters because ALS affects not only patients but also families and caregivers. The inclusion of quality-of-life, symptom management, and caregiver support topics ensures the program addresses the full human impact of the disease.

How to prepare

1. Match the stream to the project stage.
   Use the Seed Grant for early, high-risk concepts and the Development Grant for stronger, data-backed projects.

2. Build a multidisciplinary team.
   Bring together expertise that strengthens the scientific and translational value of the project.

3. Show translational value.
   Explain how the research could eventually improve care or outcomes.

4. Keep the plan feasible.
   Present methods, timelines, and resources clearly.

5. Align with priority areas.
   Make ALS relevance and impact unmistakable.

Common mistakes and tips

• Mistake: Submitting a project that is not clearly ALS-related.

  • Tip: Tie the proposal directly to ALS or the listed related diseases.

• Mistake: Using a single-discipline approach when the topic needs more breadth.

  • Tip: Add collaborators with complementary expertise.

• Mistake: Overpromising impact without enough evidence.

  • Tip: Match ambition to the maturity of the project.

• Mistake: Choosing the wrong funding stream.

  • Tip: Be realistic about whether the project is early-stage or development-ready.

FAQ

What is the total funding?

• The total funding envelope is CAD 1,500,000.

How much can each stream receive?

• Seed Grant: Up to CAD 125,000 over two years.

• Development Grant: Up to CAD 500,000 over three years.

What diseases are included?

• ALS.

• Primary lateral sclerosis.

• Progressive muscular atrophy.

• ALS/FTLD.

Who can apply?

• Research teams capable of ALS-related scientific or clinical research.

When will awards be announced?

• November 2026.

When does funding begin?

• January 2027.

Conclusion

The Brain Canada Foundation Discovery Grant Program is a strong opportunity for research teams working on ALS and related neurological diseases. Its two-stream design supports both emerging ideas and more advanced translational projects, making it a valuable pathway for meaningful scientific progress in Canada.

For more information, visit Brain Canada Foundation.